ARCA biopharma Release: Gencaro™ Cardiovascular Effect on Patients With Atrial Fibrillation Paper Published in European Journal of Heart Failure

Published: Dec 12, 2012

BROOMFIELD, Colo.--(BUSINESS WIRE)--First graph of release should read: ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation” was published in the European Journal of Heart Failure (www.escardio.org/journals/european-journal-heart-failure), a publication of the Heart Failure Association of the European Society of Cardiology (sted ARCA biopharma, Inc. (Nasdaq: ABIO) announces the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation” was published).

Back to news